DelveInsight’s “Merkel Cell Carcinoma Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of MCC epidemiology, market, and clinical development in MCC. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the MCC market trends in the United States, EU4 (Germany, France, Italy, and Spain ), the United Kingdom, and Japan.
Discover Key Insights into the Merkel Cell Carcinoma Market with DelveInsight’s In-Depth Report @ Merkel Cell Carcinoma Treatment Market Size
Key Takeaways from the Merkel Cell Carcinoma Market Report
- In January 2026, the University of Washington conducted a Phase II clinical trial to evaluate the efficacy of a combination of three immunotherapy agents in patients with advanced or metastatic Merkel cell carcinoma (MCC). The study enrolled patients whose disease had spread to lymph nodes and/or distant sites, was not amenable to surgical treatment, and had progressed despite prior PD-(L)1 inhibitor therapy. The treatment regimen included INCMGA00012 (retifanlimab; anti-PD-1), INCAGN02385 (tuparstobart; anti-LAG-3), and INCAGN02390 (verzistobart; anti-TIM-3)—all monoclonal antibodies administered intravenously at scheduled intervals. This combination therapy is designed to reinvigorate the immune system and may help inhibit tumor growth in patients who have failed anti-PD-(L)1 monotherapy.
- In January 2026, Neonc Technologies Inc. announced a Phase I/II open-label clinical trial to assess the safety, pharmacokinetics, and efficacy of repeated dosing of NEO212. The study evaluates NEO212 as monotherapy in patients with radiographically confirmed disease progression of IDH-mutant astrocytoma and IDH-wildtype glioblastoma, as well as in combination with selected standard-of-care (SOC) treatments in patients with solid tumors and uncontrolled brain metastases. The trial aims to determine the therapeutic potential of NEO212 across multiple central nervous system and metastatic tumor settings.
- In January 2026, ImmunityBio Inc. initiated a clinical study investigating combination immunotherapy approaches in patients with advanced solid tumors who had previously received PD-1/PD-L1 checkpoint inhibitors. The study is designed to evaluate the safety and efficacy of NAI (nogapendekin alfa inbakicept) in combination with other therapeutic agents, including checkpoint inhibitors and cell-based therapies, across diverse cancer types and treatment settings. Multiple patient cohorts are included based on prior therapies and tumor indications, with key endpoints focusing on overall response rate (ORR), overall survival (OS), and additional markers of anti-tumor activity and immune response.
- According to DelveInsight’s 2024 assessment, among the EU4 and the UK, Germany reported the highest incidence of MCC, accounting for approximately 25% of the total cases in the region. In contrast, Spain recorded the lowest incidence of MCC, representing about 15% of the total cases in the EU4 and the UK.
- Epidemiologic data suggest that there are approximately 2,500 new MCC cases per year within the European Union (EU), and approximately 1,000 of these patients will die from their disease.
- Approximately one-third of MCC patients eventually develop distant metastatic disease.
- Japan accounted for approximately 500 cases of MCC in 2024.
- The leading Merkel Cell Carcinoma Companies such as TuHURA Biosciences, Medicenna Therapeutics, Transgene, BioInvent, Memgen, Phio Pharmaceuticals, and others.
- Promising Merkel Cell Carcinoma Therapies include IFx-Hu2/IFx-2.0, MDNA11, BT-001, MEM-288, PH-762 and others.
Discover which Merkel cell carcinoma medications are expected to grab the market share @ Merkel Cell Carcinoma Market Size Report
Merkel Cell Carcinoma Epidemiology Segmentation in the 7MM
- Total Incident Cases of MCC
- Gender-specific Incident Cases of MCC
- Age-specific Cases Incident of MCC
- Stage-specific Cases Incident of MCC
- Total Treatable Cases of MCC in the First-line and Second-line
Download the report to understand which factors are driving Merkel Cell Carcinoma Epidemiology trends @ Merkel Cell Carcinoma Prevalence
Merkel Cell Carcinoma Marketed Drugs
- ZYNYZ (retifanlimab-dlwr): Incyte
ZYNYZ is an intravenous PD-1 inhibitor indicated in the US for the treatment of adult patients with metastatic or recurrent locally advanced MCC. In March 2023, the US FDA approved ZYNYZ for the treatment of adults with recurrent locally advanced or metastatic MCC. The Biologics License Application (BLA) for ZYNYZ for this indication has been approved under accelerated approval by the US FDA based on tumor response rate and duration of response. Incyte entered into an exclusive collaboration and license agreement with MacroGenics for global rights to ZYNYZ. ZYNYZ is a trademark of Incyte.
- BAVENCIO (avelumab): Merck KGaA (EMD Serono)
Bavencio is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Bavencio is used to treat a type of skin cancer called MCC in adults and children at least 12 years old when the cancer has spread to other parts of the body (metastatic). Bavencio is also used to treat a certain type of cancer of the bladder or urinary tract that has spread or cannot be removed with surgery. Bavencio is given for this condition after platinum cancer medicines did not work or have stopped working.
Merkel Cell Carcinoma Emerging Drugs
- IFx-Hu2/IFx-2.0: TuHURA Biosciences
IFx-2.0 is a personalized innate immune agonist that involves injecting a small amount of pDNA into a patient’s tumor, encoding an immunogenic bacterial protein expressed on the tumor’s surface. This approach leverages the patient’s innate immune system to recognize the tumor as foreign, triggering an immune response against the tumor, even if it had previously evaded immune detection. By mimicking a bacterial infection, IFx-2.0 uses the tumor itself to prime the immune system for targeted attack.
- BT-001: Transgene and BioInvent
BT-001 is an oncolytic vaccinia virus with enhanced replication selectivity in tumor cells and genetically engineered to express GM-CSF and a novel full-length anti-CTLA-4 hIgG1 mAb. Currently, the drug BT-001 is in the Phase I/II stage of clinical trials. BT-001 is being co-developed as part of a 50/50 collaboration on oncolytic viruses between Transgene and BioInvent.
Learn more about the Merkel cell carcinoma treatment options @ Merkel Cell Carcinoma Treatment Guidelines
Merkel Cell Carcinoma Market Outlook
Recent advances in treatment and surveillance are now providing hope for patients with advanced disease. Similar to recent developments in the treatment of melanoma, immunotherapy has improved patient outcomes by providing effective and durable responses for some patients with MCC. Local radiation therapy has been shown to augment this response to immunotherapies, even at sites distant from the field of radiation, a phenomenon known as the abscopal effect. Also, monitoring of antibodies to the Merkel cell polyomavirus (MCPyV) is making it easier for physicians to anticipate and monitor for recurrence. Many ongoing clinical trials are focusing on combination or experimental treatments for MCC.
Merkel Cell Carcinoma Treatment Market
Immune checkpoint inhibitors (ICIs) represent the primary treatment option for metastatic Merkel cell carcinoma and have demonstrated significant clinical benefit. If the disease recurs at the original skin site, surgical excision with wider margins is typically pursued, followed by radiation therapy if it has not been administered previously. When surgery is not a viable option, radiation therapy alone may be considered as an alternative treatment approach.
Discover more about Merkel cell carcinoma drugs in development @ Merkel Cell Carcinoma Clinical Trials
Scope of the Merkel Cell Carcinoma Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Merkel Cell Carcinoma Companies– TuHURA Biosciences, Medicenna Therapeutics, Transgene, BioInvent, Memgen, Phio Pharmaceuticals, and others.
- Merkel Cell Carcinoma Therapies- IFx-Hu2/IFx-2.0, MDNA11, BT-001, MEM-288, PH-762 and others.
- Merkel Cell Carcinoma Therapeutic Assessment: Merkel Cell Carcinoma current marketed and emerging therapies
- Merkel Cell Carcinoma Market Dynamics: Conjoint Analysis of Emerging Merkel Cell Carcinoma Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Merkel Cell Carcinoma Market Access and Reimbursement
Download the report to understand which factors are driving Merkel cell carcinoma epidemiology trends @ Merkel Cell Carcinoma Treatment Algorithm
Table of Contents
1. Key Insights
2. Merkel Cell Carcinoma Market Report Introduction
3. Merkel Cell Carcinoma Executive Summary
4. Key Events
5. Merkel Cell Carcinoma Epidemiology and Market Methodology
6. Merkel Cell Carcinoma: Market Overview at a Glance
7. Merkel Cell Carcinoma Disease Background and Overview
8. Merkel Cell Carcinoma Treatment and Guidelines
9. Merkel Cell Carcinoma Epidemiology and Patient Population
10. Merkel Cell Carcinoma Patient Journey
11. Merkel Cell Carcinoma Marketed Drugs
12. Merkel Cell Carcinoma Emerging Therapies
13. Merkel Cell Carcinoma Market Size
14. Merkel Cell Carcinoma Unmet Needs
15. Merkel Cell Carcinoma SWOT Analysis
16. Merkel Cell Carcinoma KOL Views
17. Merkel Cell Carcinoma Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
